Skip to main content

Meeting Highlights

Meeting Highlights

ASH Highlights

A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM

Meeting Highlights

ASH Highlights

Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM

Meeting Highlights

ASH Highlights

AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study

Meeting Highlights

ASH Highlights

Selinexor in Combination with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM

Meeting Highlights

ASH Highlights

Circularly Permuted TRAIL, a Novel TRAIL Agonist, with Thalidomide and Dexamethasone in Patients with RRMM

Meeting Highlights

ASH Highlights

Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis

Meeting Highlights

ASH Highlights

Teclistamab, a BCMA x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1 Study Updates

Meeting Highlights

ASH Highlights

Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

Meeting Highlights

ASH Highlights

Novel Therapeutic Strategies with P-BCMA-101 CAR T-Cells in Patients with RRMM: Phase 1/2 Study Results

Meeting Highlights

ASH Highlights

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with RRMM

2
3
4
5
6
7
8

Page 5 of 17
Results 41 - 50 of 169